REG - Syncona Limited - Publication of 2023 Annual Report & Notice of AGM

SynconaAnnouncement

28/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230628:nRSb0924Ea&default-theme=true

RNS Number : 0924E  Syncona Limited  28 June 2023

Syncona Limited

Publication of 2023 Annual Report and Notice of Annual General Meeting

28 June 2023

Syncona Ltd, a leading healthcare company focused on creating, building and
scaling a portfolio of global leaders in life science, today announces that it
has published its Annual Report and Accounts for the year ended 31 March 2023
("2023 Annual Report") and its Notice of the Annual General Meeting 2023.

In compliance with Listing Rule 9.6.1, these documents will today be filed
with the National Storage Mechanism and will shortly be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

The Notice of the Annual General Meeting 2023 is available on Syncona's
website at
https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/
(https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/)
. The 2023 Annual Report is available on Syncona's website at
https://www.synconaltd.com/investors/results-and-presentations/
(https://www.synconaltd.com/investors/results-and-presentations/) . Printed
copies of these documents are also being posted to shareholders where
requested.

Syncona's Annual General Meeting will be held at 10:30am on 1 August 2023 at
the offices of Citco Fund Services (Guernsey) Limited, Frances House, Sir
William Place, St. Peter Port, Guernsey, GY1 1GX. Shareholders are encouraged
to ensure that their votes are counted at the 2023 Annual General Meeting by
appointing the chair of the 2023 Annual General Meeting as their proxy in line
with the procedures set out in the Notice of Annual General Meeting.

Enquiries

Syncona Limited

Annabel Clark / Fergus Witt

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by
creating and building companies to deliver transformational treatments to
patients in areas of high unmet need.

 

Our strategy is to create, build and scale companies around exceptional
science to create a diversified portfolio of 20-25 globally leading life
science businesses, across development stage, modality and therapeutic areas,
for the benefit of all our stakeholders. We focus on developing treatments for
patients by working in close partnership with world-class academic founders
and management teams. Our balance sheet underpins our strategy enabling us to
take a long-term view as we look to improve the lives of patients with no or
poor treatment options, build sustainable life science companies and deliver
strong risk-adjusted returns to shareholders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFLFLSREIDFIV